784 related articles for article (PubMed ID: 19074086)
21. Treatment of pediatric primary immune thrombocytopenia with thrombopoietin receptor agonists.
Kühne T
Semin Hematol; 2015 Jan; 52(1):25-30. PubMed ID: 25578416
[TBL] [Abstract][Full Text] [Related]
22. Idiopathic thrombocytopenic purpura and dysmegakaryocytopoiesis.
Wang L; Li Y; Hou M
Crit Rev Oncol Hematol; 2007 Nov; 64(2):83-9. PubMed ID: 17900920
[TBL] [Abstract][Full Text] [Related]
23. Romiplostim: a second-generation thrombopoietin agonist.
Cohn CS; Bussel JB
Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
[TBL] [Abstract][Full Text] [Related]
24. First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat.
Rodeghiero F
Eur J Haematol Suppl; 2008 Feb; (69):19-26. PubMed ID: 18211569
[TBL] [Abstract][Full Text] [Related]
25. Emerging drugs for immune thrombocytopenia (ITP).
Salama A
Expert Opin Emerg Drugs; 2017 Mar; 22(1):27-38. PubMed ID: 28253829
[TBL] [Abstract][Full Text] [Related]
26. [Romiplostim: an advance in the treatment of idiopathic thrombocytopenic purpura].
Mingot Castellano ME
Methods Find Exp Clin Pharmacol; 2010 Dec; 32 Suppl A():39-43. PubMed ID: 21381287
[TBL] [Abstract][Full Text] [Related]
27. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.
Iraqi M; Perdomo J; Yan F; Choi PY; Chong BH
Haematologica; 2015 May; 100(5):623-32. PubMed ID: 25682608
[TBL] [Abstract][Full Text] [Related]
28. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
29. New thrombopoietic growth factors.
Kuter DJ
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S347-56. PubMed ID: 19778863
[TBL] [Abstract][Full Text] [Related]
30. [Immune thrombocytopenias: pathophysiology and treatment].
Godeau B
Bull Acad Natl Med; 2013 Feb; 197(2):407-17. PubMed ID: 24919370
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations.
Koike Y; Yoneyama A; Shirai J; Ishida T; Shoda E; Miyazaki K; Sunaga S; Horie R; Aoki K; Koike K; Ogata I; Tahara T; Kato T; Nakahara K; Kariya T; Higashihara M
Thromb Haemost; 1998 Jun; 79(6):1106-10. PubMed ID: 9657432
[TBL] [Abstract][Full Text] [Related]
32. Current therapies in primary immune thrombocytopenia.
Pels SG
Semin Thromb Hemost; 2011 Sep; 37(6):621-30. PubMed ID: 22102265
[TBL] [Abstract][Full Text] [Related]
33. Complement activation negatively affects the platelet response to thrombopoietin receptor agonists in patients with immune thrombocytopenia: a prospective cohort study.
Åkesson A; Bussel JB; Martin M; Blom AM; Klintman J; Ghanima W; Zetterberg E; Garabet L
Platelets; 2023 Dec; 34(1):2159019. PubMed ID: 36636835
[TBL] [Abstract][Full Text] [Related]
34. Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count.
Lev PR; Grodzielski M; Goette NP; Glembotsky AC; Espasandin YR; Pierdominici MS; Contrufo G; Montero VS; Ferrari L; Molinas FC; Heller PG; Marta RF
Br J Haematol; 2014 Jun; 165(6):854-64. PubMed ID: 24673454
[TBL] [Abstract][Full Text] [Related]
35. Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists.
Justo Sanz R; Monzón Manzano E; Fernández Bello I; Teresa Álvarez Román M; Martín Salces M; Rivas Pollmar MI; Jiménez Yuste V; Butta NV
Thromb Haemost; 2019 Apr; 119(4):645-659. PubMed ID: 30743272
[TBL] [Abstract][Full Text] [Related]
36. Thrombopoiesis: new ITP paradigm?
Despotovic JM; Ware RE
Blood; 2011 Jul; 118(1):1-2. PubMed ID: 21737604
[No Abstract] [Full Text] [Related]
37. The potential role of thrombopoietin in idiopathic thrombocytopenic purpura.
von dem Borne A; Folman C; van den Oudenrijn S; Linthorst G; de Jong S; de Haas M
Blood Rev; 2002 Mar; 16(1):57-9. PubMed ID: 11913997
[TBL] [Abstract][Full Text] [Related]
38. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.
Nugent D; McMillan R; Nichol JL; Slichter SJ
Br J Haematol; 2009 Sep; 146(6):585-96. PubMed ID: 19466980
[TBL] [Abstract][Full Text] [Related]
39. Current options for the treatment of idiopathic thrombocytopenic purpura.
Arnold DM; Kelton JG
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S12-23. PubMed ID: 18096468
[TBL] [Abstract][Full Text] [Related]
40. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists.
Rodeghiero F; Ruggeri M
Semin Hematol; 2015 Jan; 52(1):16-24. PubMed ID: 25578415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
